Boehringer Ingelheim International Gmbh

John D Huber

Doris Riether

Weimin Liu

Renee M Zindell

Todd Bosanac

Lifen Wu

Alessandra Bartolozzi

Heather Tye

Zhidong Chen

Stephane De Lombaert

Pui Leng Loke

Tina Marie Morwick

Ho Yin Lo

Alan Olague

Robert Owen Hughes

Brian Nicholas Cook

Qiang Zhang

Xiang Li

Ingo Andreas Mugge

Shuang Liang

Jonathon Alan Dines

Michael Robert Turner

Christopher Ronald Sarko

Thomas Martin Kirrane, Jr

Peter Allen Nemoto

Jehrod Burnett Brenneman

Brian Christopher Raudenbush

Celina Lasota

Thomas Martin Kirrane

The present invention encompasses compounds of the formula (I): wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Compounds as modulators of RORC

The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Disclosed are CCR1 inhibitor compounds of the formula (I): which are useful in the treatment of autoimmune and other diseases. Also disclosed a pharmaceutical compositions containing the same, and methods of making and using same. 

Azaindazole amide compounds as CCR1 receptor antagonists

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Oxadiazole inhibitors of leukotriene production

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I) and (IA): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, A and B are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Soluble guanylate cyclase activators

Growing community of inventors

New York, NY, United States of America

John D Huber